BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint

MT Newswires Live03-31

BioCardia (BCDA) said Monday its two-year phase 3 trial of its CardiAMP cell therapy to treat ischemic heart failure in patients with reduced ejection fraction reached no 'statistical significance' in its primary composite efficacy endpoint.

The double-blind randomized placebo-controlled trial, which involved 115 ischemic heart failure patients with reduced ejection fraction, maintained the patients on heart failure medication, while those treated with the CardiAMP minimally invasive cell therapy received a single dose adjunctive to medication.

The company said the trial results indicated increased survival and reduced major adverse cardiac and cerebrovascular events were observed throughout the study.

The company said it would share trial data with the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency to make the therapy available for physicians "as soon as possible."

Price: 2.55, Change: -0.25, Percent Change: -8.93

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2523929505?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-31 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523929505","market":"hk","top_or_hot":-1,"title":"BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BCDA\">BioCardia</a> (BCDA) said Monday its two-year phase 3 trial of its CardiAMP cell therapy to treat ischemic heart failure in patients with reduced ejection fraction reached no 'statistical significance' in its primary composite efficacy endpoint.</p><p>The double-blind randomized placebo-controlled trial, which involved 115 ischemic heart failure patients with reduced ejection fraction, maintained the patients on heart failure medication, while those treated with the CardiAMP minimally invasive cell therapy received a single dose adjunctive to medication.</p><p>The company said the trial results indicated increased survival and reduced major adverse cardiac and cerebrovascular events were observed throughout the study.</p><p>The company said it would share trial data with the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency to make the therapy available for physicians \"as soon as possible.\"</p><p>Price: 2.55, Change: -0.25, Percent Change: -8.93</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-31 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BCDA\">BioCardia</a> (BCDA) said Monday its two-year phase 3 trial of its CardiAMP cell therapy to treat ischemic heart failure in patients with reduced ejection fraction reached no 'statistical significance' in its primary composite efficacy endpoint.</p><p>The double-blind randomized placebo-controlled trial, which involved 115 ischemic heart failure patients with reduced ejection fraction, maintained the patients on heart failure medication, while those treated with the CardiAMP minimally invasive cell therapy received a single dose adjunctive to medication.</p><p>The company said the trial results indicated increased survival and reduced major adverse cardiac and cerebrovascular events were observed throughout the study.</p><p>The company said it would share trial data with the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency to make the therapy available for physicians \"as soon as possible.\"</p><p>Price: 2.55, Change: -0.25, Percent Change: -8.93</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HF","symbol_name":"绝对收益主动型ETF-DGA","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2523929505","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523929505","pubTimestamp":1743434228,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioCardia  said Monday its two-year phase 3 trial of its CardiAMP cell therapy to treat ischemic heart failure in patients with reduced ejection fraction reached no 'statistical significance' in its primary composite efficacy endpoint.The double-blind randomized placebo-controlled trial, which involved 115 ischemic heart failure patients with reduced ejection fraction, maintained the patients on heart failure medication, while those treated with the CardiAMP minimally invasive cell therapy received a single dose adjunctive to medication.The company said the trial results indicated increased survival and reduced major adverse cardiac and cerebrovascular events were observed throughout the study.The company said it would share trial data with the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency to make the therapy available for physicians \"as soon as possible.\"Price: 2.55, Change: -0.25, Percent Change: -8.93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HF":"绝对收益主动型ETF-DGA","BK4139":"生物科技","BCDA":"BioCardia"},"translate_title":"BioCardia的缺血性心力衰竭细胞治疗试验在主要复合疗效终点中未达到“统计学显著性”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCDA":1,"HF":1},"content_text":"BioCardia (BCDA) said Monday its two-year phase 3 trial of its CardiAMP cell therapy to treat ischemic heart failure in patients with reduced ejection fraction reached no 'statistical significance' in its primary composite efficacy endpoint.The double-blind randomized placebo-controlled trial, which involved 115 ischemic heart failure patients with reduced ejection fraction, maintained the patients on heart failure medication, while those treated with the CardiAMP minimally invasive cell therapy received a single dose adjunctive to medication.The company said the trial results indicated increased survival and reduced major adverse cardiac and cerebrovascular events were observed throughout the study.The company said it would share trial data with the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency to make the therapy available for physicians \"as soon as possible.\"Price: 2.55, Change: -0.25, Percent Change: -8.93","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2523929505"}